Invo Fertility highlights retrospective IVF platelet-rich plasma studies at Midwest Reproductive Symposium 2026

• Invo Fertility disclosed retrospective platelet-rich plasma studies in fertility patients, with results already presented at the 2026 Midwest Reproductive Symposium International.
• Data suggested ovarian PRP could improve IVF cycle progress in some poor responders, including enabling retrievals previously cancelled or nonproductive.
• Findings also indicated some patients developed viable embryos following prior poor outcomes, though benefits appeared less consistent in older patients.
• Subendometrial PRP was associated with improved ability to proceed to embryo transfer, with some pregnancies reported in patients with poor endometrial development.
• Company framed the work as early evidence that requires confirmation in larger prospective studies, supporting its strategy to expand adjunctive treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invo Fertility Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200900PRIMZONEFULLFEED9813263) on August 20, 2026, and is solely responsible for the information contained therein.